Loading…
Solid Biosciences Inc. is projected to rise to $9.51 by 2027, a +36% move from its current price of $7.02. SLDB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $6.76 | $7.02 | $7.29 | -0.01% |
| May 30 | $6.66 | $7.02 | $7.40 | -0.01% |
| May 31 | $6.58 | $7.02 | $7.49 | -0.02% |
| Jun 1 | $6.51 | $7.02 | $7.57 | -0.02% |
| Jun 2 | $6.45 | $7.02 | $7.63 | -0.03% |
| Jun 3 | $6.40 | $7.02 | $7.69 | -0.03% |
| Jun 4 | $6.35 | $7.02 | $7.75 | -0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.35 | $7.02 | $7.75 | -0.04% |
| Week 2 | $6.09 | $7.01 | $8.07 | -0.07% |
| Week 3 | $5.90 | $7.01 | $8.33 | -0.11% |
| Week 4 | $5.75 | $7.01 | $8.55 | -0.15% |
| Week 5 | $5.61 | $7.01 | $8.75 | -0.18% |
| Week 6 | $5.49 | $7.00 | $8.94 | -0.22% |
| Week 7 | $5.38 | $7.00 | $9.11 | -0.26% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Solid Biosciences Inc. is a healthcare company focused on developing therapies for neuromuscular and cardiac diseases in the United States. The description places the company in the Healthcare category and highlights its work on gene therapies and related platforms.
Its lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. The company also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases.
In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc.
was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Solid Biosciences Inc. (SLDB) is a healthcare company focused on therapies for neuromuscular and cardiac diseases, with a pipeline spanning several candidates at different stages. The stock currently trades at $6.62 and carries a market capitalization of $651.74M, ranking 2841 by market cap.
The current price backdrop aligns with a mixed to positive longer-term forecast. Forecasts indicate gradual upside from 2026 onward, with rising average prices across multiple years and notable upside potential by 2030, 2040, and 2050.
A major floor 33.1% below — a decisive break under it would weaken the trend.
The nearest floor, 13.4% below — buyers have tended to step in here.
The nearest ceiling, 22.9% above — a clean break opens room to run.
A major ceiling 39.5% above — clearing it would confirm fresh momentum.
Key SLDB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SLDB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.70 | Buy | $6.80 | Buy |
| MA 10 | $6.80 | Buy | $6.85 | Buy |
| MA 20 | $7.03 | Sell | $7.04 | Sell |
| MA 50 | $7.43 | Sell | $7.16 | Sell |
| MA 100 | $6.85 | Buy | $6.88 | Buy |
| MA 200 | $6.18 | Buy | $6.38 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.41 | Neutral |
| Stoch RSI (14) | 74.60 | Neutral |
| CCI (20) | -1.20 | Neutral |
| Williams %R (14) | -42.68 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -3.44 | Sell |
| Bollinger %B (20,2) | 0.50 | Neutral |
| Stochastic %K (14) | 57.32 | Neutral |
| TRIX (15) | -0.43 | Sell |
| Awesome (5,34) | -0.79 | Sell |
| Ultimate (7,14,28) | 49.59 | Neutral |
| Momentum (10) | -0.70 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 6.80 | Buy |
| ADX (14) | 13.88 | Neutral |
| ATR (14) | 0.26 | Info |
The 30-day range for SLDB is $5.12 to $8.55, signaling a defined trading band over the near term.
Sentiment is labeled BULLISH, with RSI14 at 40 and moving averages showing near-term dynamics. The 50-day simple moving average (SMA50) sits at $7.45, while the 200-day simple moving average (SMA200) is $6.17, indicating a potential uptrend relative to the longer-term average.
Support is listed at $6.08 and resistance at $8.63, framing potential bounce or breakout points within the 30-day window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.16 | $7.02 | $9.34 | 0% | Neutral | |
| $7.27 | $9.51 | $13.34 | +36% | Bullish | |
| $8.34 | $11.35 | $16.68 | +62% | Bullish | |
| $9.65 | $13.57 | $20.68 | +93% | Bullish | |
| $9.65 | $13.97 | $21.95 | +99% | Bullish | |
| $9.49 | $14.13 | $22.80 | +101% | Bullish | |
| $10.79 | $16.48 | $27.23 | +135% | Bullish | |
| $11.55 | $18.07 | $30.50 | +157% | Bullish | |
| $14.25 | $22.83 | $39.30 | +225% | Bullish | |
| $16.40 | $26.88 | $47.12 | +283% | Bullish | |
| $22.40 | $40.74 | $77.08 | +480% | Bullish | |
| $30.06 | $66.17 | $139.62 | +843% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.16 | $7.02 | $8.34 | +0.00% |
| June 2026 | $6.09 | $7.21 | $8.79 | +2.76% |
| July 2026 | $5.83 | $6.99 | $8.67 | -3.15% |
| August 2026 | $5.85 | $7.07 | $8.90 | +1.22% |
| September 2026 | $5.95 | $7.25 | $9.23 | +2.55% |
| October 2026 | $5.70 | $6.99 | $8.99 | -3.56% |
| November 2026 | $5.52 | $6.81 | $8.83 | -2.62% |
| December 2026 | $5.75 | $7.14 | $9.34 | +4.90% |
Click any year to see its month-by-month SLDB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect SLDB to range from $5.16 to $9.34 through 2026. The $7.02 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The SLDB price prediction for 2027 points to an average of $9.51 (low $7.27, high $13.34) — a potential gain of +36% on today's $7.02. Buyers look set to stay in control over this stretch.
In 2028, SLDB is projected to trade between $8.34 and $16.68, averaging $11.35 — a potential gain of +62% from today's $7.02. That is up +19% on the projected 2027 average. Momentum favours further upside here.
Solid Biosciences Inc.'s 2029 outlook centres on $13.57, within a $9.65 to $20.68 range. That is up +20% on the projected 2028 average. That marks a +93% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, SLDB could reach as high as $21.95, with a base case around $13.97 and support toward $9.65 — roughly +99% from $7.02. Momentum favours further upside here.
Expect SLDB to range from $9.49 to $22.80 through 2031. The $14.13 average target implies a +101% move from current prices. That is up +1% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The SLDB price prediction for 2032 points to an average of $16.48 (low $10.79, high $27.23) — a potential gain of +135% on today's $7.02. Momentum favours further upside here.
In 2033, SLDB is projected to trade between $11.55 and $30.50, averaging $18.07 — a potential gain of +157% from today's $7.02. That is up +10% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Solid Biosciences Inc.'s 2034 outlook centres on $22.83, within a $14.25 to $39.30 range. That is up +26% on the projected 2033 average. That marks a +225% change versus current levels. Momentum favours further upside here.
By 2035, SLDB could reach as high as $47.12, with a base case around $26.88 and support toward $16.40 — roughly +283% from $7.02. Buyers look set to stay in control over this stretch.
Expect SLDB to range from $22.40 to $77.08 through 2040. The $40.74 average target implies a +480% move from current prices. That is up +52% on the projected 2035 average. Momentum favours further upside here.
The SLDB price prediction for 2050 points to an average of $66.17 (low $30.06, high $139.62) — a potential gain of +843% on today's $7.02. Buyers look set to stay in control over this stretch.
Investing $1,000 in SLDB today (≈ 142.450142 SLDB) could be worth
$9,425.62
+$8,425.62 (+843%) by 2050 · US Dollar
Based on the average projected SLDB price of $66.17 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SLDBwould be worth at today's price.
$1,000 invested in SLDB on May 27, 2025 (≈ 328.947373 SLDB) would be worth
$2,309.21
+$1,309.21 (+130.9%) today · 2.31× · US Dollar
Based on a SLDB entry price of $3.04 vs. today's $7.02.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.47 | $1,085.01 | +8.5% |
| 1 month ago | $7.5 | $936 | -6.4% |
| 3 months ago | $6.29 | $1,116.06 | +11.6% |
| 6 months ago | $5.43 | $1,292.82 | +29.3% |
| 1 year ago | $3.04 | $2,309.21 | +130.9% |
| All time (5.0y) ago | $56.25 | $124.8 | -87.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SLDB forecast.
Our base-case forecast reaches $14.00 around 2031.
Implied market cap at $14.00: $1.38B
The multi-year forecast shows a bullish trajectory over the coming years, with each successive year generally delivering higher average prices.
For 2026, the forecast shows an average of $6.62 with a neutral sentiment and a min of $5.16 and a max of $8.90, implying little immediate directional certainty but a baseline around the current price.
Key long-horizon milestones include 2030 with an average of $13.13 and a return around 98.3%, followed by 2040 with an average of $38.42 and a return around 480.3%, and 2050 with an average of $62.09 and a return around 838%. The forecast also points to notable higher-year maxima, culminating in a max of $133.06 by 2050, underscoring the potential upside under favorable conditions.
These figures illustrate a rising growth path over time, balanced by the reality that forecasts are estimates and not guarantees, with outcomes influenced by clinical progress, regulatory decisions, and broader market factors.
Tap a question to reveal the answer.
2030 average price is $13.13, with a min of $8.98 and a max of $20.81; ROI is 98.3% and sentiment is BULLISH.
The forecast shows upside from 2027 onward (avg rising to $8.98 in 2027 and to $62.09 by 2050 with ROI up to 838%), though near-term 2026 is neutral at an average of $6.62.
Yes. The 2050 max forecast is $133.06, which exceeds $100.
Current price is $6.62 and market cap is $651.74M.
The 30-day range is $5.12 to $8.55; sentiment is BULLISH, RSI14 is 40; SMA50 is $7.45 and SMA200 is $6.17; support is $6.08 and resistance is $8.63.
Solid Biosciences Inc. Community Discussion
0Share your Solid Biosciences Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.